Publications Authored by April A N Rose

BRAF Mutation Class and Clinical Outcomes-Letter.

Authors:

Clin Cancer Res 2019 May;25(10):3188

Faculty of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada.

Download full-text PDF	Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0080	DOI Listing

May 2019

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.

Authors:

Matthew Dankner Mathieu Lajoie Dan Moldoveanu Tan-Trieu Nguyen Paul Savage Shivshankari Rajkumar Xiu Huang Maria Lvova Alexei Protopopov Dana Vuzman David Hogg Morag Park Marie-Christine Guiot Kevin Petrecca Catalin Mihalcioiu Ian R Watson Peter M Siegel April A N Rose

Clin Cancer Res 2018 12 14;24(24):6483-6494. Epub 2018 Jun 14.

Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF	Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107	Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-3384	DOI Listing

December 2018

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:

Matthew Dankner April A N Rose Shivshankari Rajkumar Peter M Siegel Ian R Watson

Oncogene 2018 06 15;37(24):3183-3199. Epub 2018 Mar 15.

Goodman Cancer Research Centre, McGill University, Montreal, QC, Canada.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1038/s41388-018-0171-x	DOI Listing

June 2018

Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.

Authors:

Matthew Dankner April A N Rose

Br J Cancer 2018 05 22;118(9):1276-1277. Epub 2018 Mar 22.

Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1038/s41416-018-0012-2	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943260	PMC

May 2018

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Authors:

April A N Rose Marco Biondini Rafael Curiel Peter M Siegel

Pharmacol Ther 2017 Nov 22;179:127-141. Epub 2017 May 22.

Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada; Department of Medicine, McGill University, Montréal, Québec, Canada; Department of Biochemistry, McGill University, Montréal, Québec, Canada; Department of Anatomy and Cell Biology, McGill University, Montréal, Québec, Canada; Department of Oncology, McGill University, Montréal, Québec, Canada. Electronic address:

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.pharmthera.2017.05.010	DOI Listing

November 2017

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

Authors:

April A N Rose Matthew G Annis Dennie T Frederick Marco Biondini Zhifeng Dong Lawrence Kwong Lynda Chin Tibor Keler Thomas Hawthorne Ian R Watson Keith T Flaherty Peter M Siegel

Clin Cancer Res 2016 Dec 11;22(24):6088-6098. Epub 2016 Aug 11.

Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1192	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168941	PMC

December 2016

Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.

Authors:

Sébastien Tabariès Véronique Ouellet Brian E Hsu Matthew G Annis April A N Rose Liliane Meunier Euridice Carmona Christine E Tam Anne-Marie Mes-Masson Peter M Siegel

Breast Cancer Res 2015 Mar 27;17:45. Epub 2015 Mar 27.

Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, Room 513, Montréal, QC, H3A 1A3, Canada.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1186/s13058-015-0558-3	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413545	PMC

March 2015

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Authors:

Johanna Bendell Mansoor Saleh April A N Rose Peter M Siegel Lowell Hart Surendra Sirpal Suzanne Jones Jennifer Green Elizabeth Crowley Ronit Simantov Tibor Keler Thomas Davis Linda Vahdat

J Clin Oncol 2014 Nov 29;32(32):3619-25. Epub 2014 Sep 29.

Johanna Bendell and Suzanne Jones, Sarah Cannon Research Institute, Nashville, TN; Mansoor Saleh, Georgia Cancer Specialists, Atlanta, GA; April A.N. Rose and Peter M. Siegel, Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers; Surendra Sirpal, Hematology Oncology Associates, Lake Worth, FL; Jennifer Green, Elizabeth Crowley, Ronit Simantov, Tibor Keler, and Thomas Davis, Celldex Therapeutics; and Linda Vahdat, Weill Cornell Medical College, New York, NY.

View Article